Inflammation and Autoimmunity

Developing novel treatments for a breadth of inflammatory and autoimmune diseases

Seeking to develop best-in-class and first-in-class treatments for a breadth of inflammatory and autoimmune diseases with unmet medical needs

Leveraging our strength and expertise in immunology science, our research efforts are focused on gaining a better understanding of the common biology and shared molecular pathways among inflammatory and autoimmune diseases, as well as the fundamental drivers and mechanisms of disease. This approach enables us to identify and select drug targets that have the potential to effectively treat not just one, but multiple inflammatory and autoimmune diseases. Through our advancements in this field, we aim to bring value to the broader scientific community, help redefine standards of care and, ultimately, deliver breakthrough medicines that transform the lives of patients worldwide.

Focusing on unmet medical needs

  • Gout

    Gout is a chronic metabolic inflammatory disease caused by the build-up of uric acid crystals

    Learn more
  • Lupus

    Lupus attacks healthy tissue in the body, including skin, joints, the brain and blood vessels

  • Rheumatoid arthritis

    Rheumatoid arthritis is a painful, systemic, chronic inflammatory autoimmune disease which causes damage to the joints and vital organs



Day in the life – Micki Hultquist: committed to Lupus

Our pipeline

Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.

Phase 3/Reg.* refers to assets that are in Phase 3 or that have been submitted for regulatory approval, and may include assets that are now launched in one or more major markets.

Respiratory, Inflammation and Autoimmunity (as at 28 July 2016)

Phase 1

Phase 1

  • AZD1419 asthma
  • AZD5634 cystic fibrosis
  • AZD7986 COPD
  • AZD8871 COPD
  • AZD9567 rheumatoid arthritis
  • MEDI0700 systemic lupus erythematosus
  • MEDI4920 primary Sjögren’s syndrome
  • MEDI5872 SLE
  • MEDI9314 atopic dermatitis
  • anifrolumab systemic lupus erythematosus (subcutaneous)
  • lesinurad+allopurinol FDC chronic treatment of hyperuricemia in patients with gout

Phase 2

Phase 2

  • AZD7594 asthma/COPD
  • AZD7624 COPD
  • AZD9412 asthma/COPD
  • MEDI2070 Crohn’s disease
  • PT010 asthma
  • abediterol asthma/COPD
  • anifrolumab lupus nephritis
  • inebilizumab neuromyelitis optica
  • mavrilimumab rheumatoid arthritis
  • tezepelumab asthma/atopic dermatitis
  • tralokinumab atopic dermatitis
  • verinurad chronic treatment of hyperuricemia in patients with gout

Phase 3/Reg.*

Phase 3/Reg.*

  • Bevespi Aerosphere (PT003) GFF PINNACLE COPD
  • PT010 COPD
  • Zurampic (lesinurad) CLEAR 1,2 CRYSTAL chronic treatment of hyperuricemia in patients with gout
  • anifrolumab TULIP systemic lupus erythematosus
  • benralizumab CALIMA SIROCCO ZONDA BISE BORA GREGALE severe asthma
  • benralizumab TERRANOVA GALATHEA COPD
  • brodalumab AMAGINE-1,2,3 psoriasis
  • tralokinumab STRATOS 1,2 TROPOS MESOS severe asthma

LCM Projects

LCM Projects

  • Duaklir Genuair COPD
  • Symbicort breath actuated Inhaler asthma/COPD
  • Symbicort SYGMA as-needed use in mild asthma

    

Commitment to science

Our commitment to science is reflected in our track record of publications. Here are a few recent examples of high impact and high quality publications co-authored by AstraZeneca and/or MedImmune scientists.

Targeting phosphatase-dependent proteoglycan switch for rheumatoid arthritis therapy

PUBLISHED
May 2015

TITLE
Targeting phosphatase-dependent proteoglycan switch for rheumatoid arthritis therapy

AstraZeneca/MedImmune AUTHOR
Tomas Mustelin (MedImmune)

Resources


Events and talks

Learn more about our disease areas, data and products

2016

Upcoming events

We have no upcoming events at the moment. Please look again soon as events will be added nearer to the time

Page Atlas ID: 958748.011
Date of next review: March 2017